Orikami completes Proof of Concept phase on track to personalize lung cancer patient journey.
Elderly lung cancer patients are often over and undertreated due to the combination of standard treatment protocols in a highly heterogeneous patient population and the lack of a widely adopted monitoring solution to balance treatment effectiveness with quality of life.
In 2022, Orikami started, supported by Amgen Netherlands, a 3-year program to develop a digital biomarker tool for patients and physicians enabling them to remotely monitor a patient’s frailty and resilience. After the needs and wishes of patients and physicians were explored in the initial Discovery phase, we developed a first version of the product in the Proof of Concept phase. Currently, Orikami prepares a next version of the product to start collecting real world evidence in the upcoming validation studies.
Curious to learn more? Please visit this interview about the program here: